Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy

Isocitrate dehydrogenase-2 (IDH2) is a mitochondrial enzyme that catalyzes the metabolic conversion between isocitrate and alpha-ketoglutarate ( α-KG) in the TCA cycle. IDH2 mutation is an oncogenic event in ac...

Source: Journal of Hematology and Oncology - March 21, 2022 Category: Hematology Authors: Peiting Zeng, Wenhua Lu, Jingyu Tian, Shuang Qiao, Jiangjiang Li, Christophe Glorieux, Shijun Wen, Hui Zhang, Yiqing Li and Peng Huang Tags: Research Source Type: research